GROWTH HORMONE AXIS / FAQ
Direct Questions, Citation-Anchored Answers
What readers most often ask about ipamorelin, CJC-1295, and sermorelin — answered from the published record, not from community consensus.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid (pentapeptide) research compound that selectively activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) on pituitary cells, triggering a pulse of growth hormone release. Its defining property is selectivity: it releases GH comparably to earlier GHRPs but without the cortisol and prolactin elevation those compounds produce [6]. It is not an approved drug anywhere and is sold for laboratory research use only.
What does ipamorelin do for you?
That question assumes a clinical benefit established in humans — which the record does not support for any indication. In healthy volunteers, IV ipamorelin produced a dose-dependent GH pulse peaking roughly 40 minutes after dosing [4]. In a Phase 2 trial of 114 adults recovering from bowel surgery, it did not significantly reduce time to first tolerated meal compared to placebo (primary endpoint not met, p=0.15) [3]. Common community claims — improved sleep, recovery, body composition — are anecdotal and not established by controlled trials. This site does not describe personal benefits or advise on use.
What is ipamorelin peptide?
"Ipamorelin peptide" is informal language for ipamorelin — a synthetic peptide with the chemical sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The unusual amino acids at positions 1, 3, and 4 (alpha-aminoisobutyric acid and D-configured residues) resist enzymatic breakdown, giving the compound a usable pharmacokinetic window despite being a small molecule. It was characterized in 1998 as the first highly GH-selective growth hormone secretagogue [6].
What are the risks of ipamorelin?
The documented and reasoned risk signals are these. First, a 28-day preclinical study of a structurally distinct but pharmacologically related GHS-R1a agonist found dose-dependent myocardial degeneration in rats — a class-level cardiovascular signal without a human counterpart [2]. Second, GH counter-regulates insulin; ipamorelin also has GH-independent insulinotropic effects on pancreatic tissue, creating unpredictable glycemic impact in subjects with insulin resistance [6]. Third, there are no long-term human safety data — the only controlled human studies lasted 7 days (Phase 2 trial) or used acute single-dose IV infusions [3][4]. Fourth, research-grade material from unregulated suppliers is not quality-assured for purity or identity.
What is CJC-1295?
CJC-1295 is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH), built on the first 29 residues of the natural molecule with four stabilizing amino-acid substitutions. The DAC (Drug Affinity Complex) variant adds an albumin-binding moiety that extends its half-life to approximately 5.8–8.1 days, sustaining GH and IGF-1 elevation from a single dose for days [11]. The no-DAC variant (Modified GRF 1-29) carries only the stabilizing substitutions and has a much shorter half-life. CJC-1295 is a research compound, not an approved drug.
What does CJC-1295 do?
In two published human pharmacology studies, CJC-1295 produced sustained, dose-dependent elevation of both GH and IGF-1 while preserving pulsatile GH secretion [11][12]. A single subcutaneous dose raised mean plasma GH two- to ten-fold for six or more days and kept IGF-1 above baseline for 9–11 days. Basal GH rose approximately 7.5-fold in a second study. These are pharmacokinetic and pharmacodynamic observations in healthy volunteers — there is no completed controlled trial of what CJC-1295 does to any disease state, body-composition outcome, or aging parameter.
Is CJC-1295 safe?
The published human data — two small PK studies in healthy volunteers — do not report significant adverse events, but they are short-term pharmacology observations, not safety trials. No long-term human safety study of CJC-1295 has been conducted. Relevant theoretical concerns include IGF-1-driven oncologic risk from sustained elevation, sodium retention, and insulin sensitivity effects — the same axis effects that make GH excess (acromegaly) a serious clinical condition [8]. The FDA's 2024 Pharmacy Compounding Advisory Committee review cited immunogenicity and safety concerns for this compound class.
How much CJC-1295 should I take?
This desk does not advise on human doses. The published human PK studies used subcutaneous doses of 30–90 micrograms/kg in healthy research volunteers [11][12] — those are pharmacology study parameters, not treatment recommendations. CJC-1295 is a research compound with no approved human indication. Any dosing protocol in clinical or community use is outside the peer-reviewed evidence base.
What is sermorelin?
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal bioactive fragment of growth hormone-releasing hormone (GHRH(1-29)). It is the shortest GHRH fragment that retains full receptor activity. It was previously FDA-approved as a drug for pediatric growth hormone deficiency, commercially withdrawn in 2008 for business reasons (not a safety or efficacy failure), and is now prepared by compounding pharmacies under FDA's Category 1 interim 503A policy [15][16].
What does sermorelin do to the body?
Sermorelin binds the GHRH receptor on anterior-pituitary somatotrophs and activates cAMP/PKA signaling to stimulate pulsatile growth hormone release — the body's own GH, under its own feedback regulation, rather than exogenous GH supplied from outside. In prepubertal children with GH deficiency, once-daily subcutaneous sermorelin raised first-year height velocity from approximately 4.1 cm/year to roughly 7–8 cm/year [16]. In adults, the strongest RCT data for the mechanism class comes from a related compound (tesamorelin, not sermorelin) and showed favorable cognitive effects and body-fat reduction in older adults over 20 weeks [13].
Does sermorelin work?
For its approved indication — pediatric growth hormone deficiency — the controlled evidence says yes: a multicenter trial demonstrated significantly accelerated linear growth [16]. For adult anti-aging or wellness use, an Annals of Internal Medicine editorial explicitly judged GH-secretagogue interventions for aging "not yet ready for prime time" [14]. Marketing claims for adult body recomposition or anti-aging are not backed by controlled efficacy trials of sermorelin in healthy adults. "Does it work" depends heavily on for what.
How long does it take for sermorelin to work?
Mechanistically, sermorelin acts quickly — it binds the GHRH receptor and triggers a GH pulse within the time frame of normal pituitary signaling. Whether any downstream physiologic change follows, and over what timescale, depends on the indication and the individual. In the pediatric GH-deficiency trial, height-velocity changes were measured over a full year [16]. In healthy adults, this question is largely uncharacterized in controlled studies — there are no published sermorelin-specific human trials reporting response timelines for body composition, cognition, or any other adult endpoint.